Lockerman Financial Group Inc. Acquires New Stake in Amgen Inc. (NASDAQ:AMGN)

Lockerman Financial Group Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,111 shares of the medical research company’s stock, valued at approximately $316,000.

Other institutional investors have also bought and sold shares of the company. Diversified Trust Co boosted its position in Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after acquiring an additional 16,376 shares during the last quarter. Provence Wealth Management Group boosted its position in Amgen by 11.9% during the fourth quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock valued at $416,000 after acquiring an additional 154 shares during the last quarter. Kinsale Capital Group Inc. boosted its position in Amgen by 33.0% during the fourth quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock valued at $3,269,000 after acquiring an additional 2,814 shares during the last quarter. Global Wealth Management Investment Advisory Inc. boosted its position in Amgen by 2.4% during the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock valued at $1,363,000 after acquiring an additional 109 shares during the last quarter. Finally, Traynor Capital Management Inc. boosted its position in shares of Amgen by 9.5% during the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after purchasing an additional 1,650 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.69% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Argus increased their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Raymond James assumed coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Truist Financial reissued a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Finally, William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $307.35.

Amgen Trading Up 0.7 %

NASDAQ:AMGN traded up $2.08 during trading hours on Friday, reaching $315.77. The company’s stock had a trading volume of 190,295 shares, compared to its average volume of 2,764,467. The firm has a market capitalization of $169.39 billion, a price-to-earnings ratio of 44.81, a PEG ratio of 2.83 and a beta of 0.60. The firm has a 50-day simple moving average of $299.67 and a 200-day simple moving average of $291.67. Amgen Inc. has a 1 year low of $218.44 and a 1 year high of $329.72. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm’s revenue was up 22.0% compared to the same quarter last year. During the same quarter last year, the company earned $3.98 EPS. Research analysts expect that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.